Cyclic Glycine-Proline vs Retatrutide
Moderate Research vs Extensively Studied
monitor Mechanism-based · 47% Both Cyclic Glycine-Proline and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Cyclic Glycine-Proline Retatrutide
Weight 154.17 Da 4,731.33 Da
Half-life Extended stability (more stable than linear GPE precursor) ~6 days
Chain 2 amino acids (cyclic) 39 amino acids
Type Cyclic dipeptide (2,5-diketopiperazine) Triple GLP-1/GIP/glucagon agonist
Key Benefits
Cyclic Glycine-Proline
01 Neuroprotection and cognitive enhancement
02 IGF-1 optimization
03 Cardiovascular support
04 Metabolic health improvement
05 Blood-brain barrier penetration
06 Convenient oral administration
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Cyclic Glycine-Proline
20-100 μg daily (or 300mg blackcurrant extract 2x daily) / Once daily, preferably in the morning
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Cyclic Glycine-Proline
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Consult healthcare provider if taking IGF-1 or growth hormone medications
Limited long-term human data available
Not studied in pregnancy
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Cyclic Glycine-Proline Retatrutide
Status Moderate Research Extensively Studied
References 4 studies 6 studies
Latest — 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.